Press Releases

In their quest to overcome health disparities, University of Utah Health scientists are launching SCALE-UP II and SCALE-UP Counts, a pair of initiatives designed to increase COVID-19 testing and vaccination among rural and underserved populations. Combined, the two initiatives are supported by $4.7 million from the National Institutes of Health (NIH).

The Pancreatic Cancer Action Network has announced the latest updates to its innovative adaptive clinical trial, Precision PromiseSM, including the addition of an investigational treatment from global healthcare company, Novartis, as well as the opening of five additional sites across the country, including at Huntsman Cancer Institute.

Huntsman Cancer Institute awarded $50,000 by American Cancer Society to fund transportation and lodging for cancer patients and their loved ones. Amy Horyna, MSW, says, "This gift will make a huge difference by allowing us to deliver assistance directly to patients who need it most."

The LGBTQ+ Healthcare Equality Leader designation highlights Huntsman Cancer Institute’s commitment to equity, diversity, and inclusion, and its work to foster a culture of belonging for all, including those who identify as LGBTQ+.

Huntsman Cancer Institute announces Ashlee Harrison, MPA, as executive director of innovation and transformation. The Innovation and Transformation Office supports Huntsman Cancer Institute in taking on new challenges with agility and accelerating progress toward a cancer-free frontier.

Researchers at Huntsman Cancer Institute are developing breast cancer models using tumors donated by patients to narrow the number of drugs that might be effective in each tumor based on the unique characteristics and behavior in these models of cancer.

Huntsman Cancer Institute at the University of Utah is one of the select sites in the United States to offer a new clinical trial for glioblastoma patients, called GBM AGILE. The clinical trial is using an approach that offers study participants multiple new glioblastoma drugs from different pharmaceutical companies.

The ColoCare Study, a major international study of colorectal cancer, has received a five-year renewal and $10 million to fund colorectal cancer treatment innovations. This next phase of the project will use research findings from the ColoCare Study to develop new medical interventions.